Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...

Illumina expects that adding SomaLogic will aid its “multiomics” business strategy and strengthen the value of its gene ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...